Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2014

View Archived Issues

FDA grants orphan drug status to Re-188-P2045 for pancreatic cancer

TiGenix to develop allogeneic stem cell therapy for early RA and sepsis

Aclaris Therapeutics reports data from phase II trial of A-101 in seborrheic keratosis

FDA grants orphan drug status to two pulmonary disease treatments

VIB and Spain's CNIO partner for drug discovery

FDA grants small business waver of PDUFA fee for Rockwell's Triferic

Xenetic Biosciences reports safety data from ongoing phase II study of ErepoXen

Italian researchers patent novel LSD1 inhibitors

Novel SYK inhibitors prepared by Hutchison MediPharma

Roche designs new immunoproteasome inhibitors

Roche prepares new CB2 receptor agonists

Boehringer Ingelheim discloses novel GPR40 agonists

University of Bath designs novel products for cancer

Phase II study of DARPin abicipar pegol supports progressing to phase III

Phase I data reported for REGN-1400 in patients with cancer

Hanmi Pharmaceuticals and Kinex Pharmaceuticals report data from phase I/II trial of Oraxol

Clinical trial of cancer vaccine ETBX-011 completed

Vertex submits sNDA for Kalydeco in adults with CF and the R117H mutation

IND application submitted for ProHema in inherited metabolic disorders

Imaging neuroinflammation with a novel PET tracer

Amicus provides update on second phase III study of migalastat for Fabry disease

ISIS-GCGRRx improves glycemic control in type 2 diabetes trial

Ipsen submits applications in the U.S. and E.U. for Somatuline

BioAlliance Pharma and Topotarget approve merger to create Onxeo

Actavis completes acquisition of Forest Laboratories, Furiex in favor of its acquisition

FDA awards breakthrough therapy designation to blinatumomab in ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...